Spots Global Cancer Trial Database for A Large-scale Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Large-scale Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96
Official Title: A Large-scale Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96
Study ID: NCT03650257
Conditions
Study Description
Brief Summary: This trial is to further study the safety and effectiveness of autologous gp96 treatment of glioblastoma on the basis of preliminary work.
Detailed Description: RATIONALE: heat shock protein gp96-peptide complex made from a person's tumor cells may help the body build an effective immune response to kill tumor cells. Overall Goals: - to evaluate the safety and induction of anti-tumor immunity by administration of an immunogenic human tumor cell vaccine, and assess immune response in relation to clinical outcome. Primary Aim: - to further evaluate effectiveness of autologous gp96 treatment of glioblastoma on the basis of preliminary work. Secondary Aims: to study the immune response to vaccination, to monitor clinical responses , to further the safety of vaccine.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing, Beijing, China
Contact Details
Name: zhixian Gao, Doctor
Affiliation: Beijing Tiantan Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
